

# MUSHROOMS INC. UPDATES

## March 2024

Outstanding Shares: 39,435,760 (Unchanged)

Restricted: 30,736,303 (unchanged)

Unrestricted: 8,699,457 (unchanged)



### Corporate Structure and Shareholder Confidence:

Mushrooms Inc. has not issued any additional stock since September of 2023. We continue to maintain a strong share structure, reflective of our commitment to company growth and shareholder value. Our financial health is robust, and keeps us positioned well for the advancements of both investment-infusion and growth. We still see the stock is volatile with a trade of even 1000 shares moving it substantially up or down. Volume has fluctuated as well and this is to be expected as a public yet pre-revenue company positioned well for substantial growth.

**Overview:** As spring ushers in a season of renewal and growth, our team at Mushrooms Inc. is thrilled to share with you the blossoming developments that are setting the stage for an exciting future. In this edition of our monthly newsletter, we delve into the fresh beginnings of our company blog, our collaboration with AI-driven marketing expertise, and significant strides towards patent validation through tangible prototypes.

**Introducing Our Company Blog** Our journey is filled with unique stories, challenges, and milestones that we are eager to share with you. We've launched a new blog as a platform to dive deeper into the intricacies of being a start-up in the OTC market, share our progress in multiple areas including product development, and open the floor to discussions that matter to you.

Our initial posts explore the benefits and challenges of being publicly traded early on and the impact it has on our growth strategy as well as our Sport+ product. Join us [\[here\]](#), where we embrace transparency, engage in meaningful conversations, and learn together.




Image credit: Jan-Erik Asplund - Published Sep 09th, 2020

**Embracing AI for a Strategic Edge** In an era where innovation is key to staying ahead, Mushrooms Inc. has partnered with AI-trained professional to redefine our marketing and sales strategies. This collaboration aims to harness the power of artificial intelligence to enhance our digital presence, optimize our product sales, and deliver content that resonates with our audience. We're excited about the potential of AI to help us connect more effectively with you and pave the way for groundbreaking marketing approaches.



**Prototyping:** Bringing Our Patent to Life One of the most exhilarating updates we have for you involves the progress on our patent. We are now in the phase of developing prototypes that embody our innovative solutions in bacterial detection and nutrient delivery. The teams that are coming together to create the prototypes are creating more than a proof of concept; they are creating the tangible sample of our bandage and threads for the medical industry to see and feel. This is a testament to our commitment to revolutionizing the medical industry with sustainable and effective alternatives. Investors and medical professionals will have the opportunity to experience our innovation firsthand - to touch, see, and understand the potential impact of our work on global health challenges. Exact timelines and progress will be shared as we move along.

Looking Ahead As we continue to navigate through these exciting developments, your support and feedback remain invaluable to us. Our Newsletter video reached over 3000 views in a few days and we will be creating more videos to our [youtube channel] from our CEO and other key team members. Whether it's engaging with our blog, sharing your thoughts on our AI-enhanced strategies, or expressing interest in our upcoming prototypes, we invite you to be an active part of our journey.

Thank you for being with us every step of the way. Together, we're not just growing mushrooms; we're cultivating a healthier, more sustainable future. Warm regards,

## **About Mushrooms Inc.**

[Mushrooms Inc.](#) (OTC: MSRM) is a publicly traded company on the OTC Markets with the stock symbol MSRM and is the first industrial mushroom company to be listed on a public exchange. Mushrooms Inc. is a pioneering biotech company, deeply entrenched in the world of mycology. Our primary mission is to harness the transformative potential of Mycelium, especially for groundbreaking applications in the healthcare sector. Our dedicated R&D endeavors are underpinned by advanced technology, ensuring rigorous testing and validation of the manifold health benefits of mushrooms, thereby leading to the formulation of scientifically backed supplements.

Our recent patent underscores our innovation-driven ethos, detailing novel methods for bacterial detection and nutrient delivery using mycelium. This patent stands as a testament to our commitment to intertwining age-old wisdom with contemporary technological advancements, aiming to revolutionize healthcare interventions and amplify overall well-being. Inspired by the vision and resilience of mycology pioneers, Mushrooms Inc. establishes robust partnerships, resulting in products that champion both human health and environmental sustainability.

## Safe Harbor Statement

This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance or guarantee that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: adverse economic conditions, competition, adverse federal, state and local government regulation, international governmental regulation, inadequate capital, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other specific risks. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.